Cyclopamine

Catalog No.S1146

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Cyclopamine Chemical Structure

Cyclopamine Chemical Structure
Molecular Weight: 411.62

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Hedgehog/Smoothened Inhibitors with Unique Features

  • Selective Smoothened inhibitor

    PF-5274857 Smoothened-selective, IC50=5.8 nM.

  • Smoothened Inhibitor in Clinical Trial

    LDE225 (NVP-LDE225,Erismodegib) Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).

  • Newest Smoothened Inhibitor

    GANT61 Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Smoothened Activator

    Purmorphamine Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Product Information

  • Compare Hedgehog/Smoothened Inhibitors
    Compare Hedgehog/Smoothened Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets Smoothened [1]
(TM3Hh12 cells)
IC50 46 nM
In vitro Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
OS-RC-2NETW[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDEfm45UUN3ME21Mlg3PjZizszNMlXTV2FPT0WU
DOHH-2MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfuUI9ZUUN3ME25MlM2Pjh7IN88US=>MlTPV2FPT0WU
no-10MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInPVoRKSzVyPUmuPVA{QSEQvF2=NVXKXFA2W0GQR1XS
LS-513Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Xrd2lEPTB;MUGuN|U1PyEQvF2=MXXTRW5ITVJ?
ALL-POMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XlR2lEPTB;MUGuO|c{PCEQvF2=MmryV2FPT0WU
8-MG-BAMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX4TWM2OD1zMz6xNVI{KM7:TR?=NIX4O|BUSU6JRWK=
RPMI-8402MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvrdZhKSzVyPUG1Mlg2OzdizszNMofaV2FPT0WU
EoL-1-cellNVfQdINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Xzd2lEPTB;MUiuOVk1QCEQvF2=M4fER3NCVkeHUh?=
NALM-6MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF7LkCxOlch|ryPMW\TRW5ITVJ?
DELNGqxR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;EbVZGUUN3ME2yNE4yPDdzIN88US=>MXzTRW5ITVJ?
SRM2ryO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LjNGlEPTB;MkOuOlcyPSEQvF2=M37BVXNCVkeHUh?=
697M{\remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH20cFBKSzVyPUK2MlYyPTVizszNMke2V2FPT0WU
COLO-829NILoO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTQTWM2OD1{Nj64OFg{KM7:TR?=NWXtXnA5W0GQR1XS
EVSA-TMoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTJ5LkW1OlEh|ryPNW\E[YJMW0GQR1XS
ATN-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[wTWM2OD1|MT6yN|I6KM7:TR?=M4X1[HNCVkeHUh?=
L-363MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTYc5M6UUN3ME2zNU44PDZzIN88US=>MlLwV2FPT0WU
LAMA-84MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTN{LkWyNVEh|ryPNFjZO2dUSU6JRWK=
NOS-1MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlviTWM2OD1|ND6yPVU3KM7:TR?=Mn73V2FPT0WU
BB30-HNCNWmzXlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTN2LkOzNFYh|ryPMl3sV2FPT0WU
BC-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPwZnVKSzVyPUO3Mlk4PDZizszNMUDTRW5ITVJ?
IST-SL2NHvROFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvIPHNKSzVyPUO4MlIzPCEQvF2=M1\uc3NCVkeHUh?=
D-392MGMkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTRyLkKyNVUh|ryPNXTMPIVNW0GQR1XS
no-11NIHv[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fpUmlEPTB;NECuOVUzOSEQvF2=NUfvSYh6W0GQR1XS
LC4-1NUXNXnpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfZSJlKSzVyPUSwMlg4OTZizszNMmCyV2FPT0WU
A388MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\lcWlEPTB;NEKuOVg1QCEQvF2=NUfUVmc{W0GQR1XS
NTERA-S-cl-D1NYPVTWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTJc|RKSzVyPUSyMlcxPzRizszNMVXTRW5ITVJ?
CESSMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTR2LkKyN|Ih|ryPMWDTRW5ITVJ?
RS4-11MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnJeJBKSzVyPUS5MlA6OzhizszNNUPqZ2MzW0GQR1XS
MS-1NFX5TnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DPfGlEPTB;NUCuPVM2OSEQvF2=M4S1PXNCVkeHUh?=
CTV-1MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Lj[2lEPTB;NUGuNFc1KM7:TR?=MXrTRW5ITVJ?
D-502MGNI\kb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTVzLk[yO|Eh|ryPMoDBV2FPT0WU
ML-2NFvkbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLITWM2OD13Mj65NVk2KM7:TR?=NWDMWnRbW0GQR1XS
SK-NEP-1NISyOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XodGlEPTB;NUOuN|kzOyEQvF2=NVPUPXI5W0GQR1XS
LOXIMVIMl\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTV|LkW4PFQh|ryPNEDWPG5USU6JRWK=
DJM-1M1v1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\5TWM2OD13Nj6zN|kyKM7:TR?=NVOy[oJuW0GQR1XS
GI-1NUW5O4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETteVJKSzVyPUW2MlYyPDlizszNMXXTRW5ITVJ?
IST-MES1M3nWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\lR2lEPTB;NkCuOVQ6OyEQvF2=NUXtcm06W0GQR1XS
MV-4-11M1nSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELQTFNKSzVyPU[wMlY2OzhizszNNUnUTIFEW0GQR1XS
OVCAR-4NH3CfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;I[2lEPTB;NkOuOVY2PyEQvF2=MmnqV2FPT0WU
KE-37MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LJUWlEPTB;Nk[uNlY3QCEQvF2=M4LxTXNCVkeHUh?=
D-542MGNWnaRoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPvTWM2OD14OD60NVM2KM7:TR?=MkfyV2FPT0WU
MHH-PREB-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXu4OXF{UUN3ME23Nk45PDRzIN88US=>M3TUVXNCVkeHUh?=
MRK-nu-1MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDZO5pKSzVyPUezMlQ4ODVizszNNEmyNmxUSU6JRWK=
D-247MGNHX6RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnm1TWM2OD15Mz61OFQzKM7:TR?=MmDwV2FPT0WU
OCI-AML2MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLiXYdKSzVyPUe2Mlk{PjlizszNMl;vV2FPT0WU
LP-1MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULu[HIyUUN3ME24Nk45PzNzIN88US=>MkOzV2FPT0WU
HCC1599MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4L6XGlEPTB;OESuNlg{PyEQvF2=NI\GbWxUSU6JRWK=
KARPAS-45MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrpSpdwUUN3ME24OE43QTl{IN88US=>MXvTRW5ITVJ?
BE-13M1;s[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF60dFZKSzVyPUm5MlA1PzdizszNM1nmbHNCVkeHUh?=
GCIYNV\3bXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUO5TZZKUUN3ME25PU4xQTV2IN88US=>NYLMNGZ1W0GQR1XS
BV-173NXPsXGs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\1[GFKSzVyPUGwNE4{OjVizszNMW\TRW5ITVJ?
LB2518-MELNHjFO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFyMD63PFkh|ryPNYCxO3hnW0GQR1XS
KS-1NH3vXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoD1TWM2OD1zMEGuOlM6KM7:TR?=NHe0VoFUSU6JRWK=
MOLT-16NHX2SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TsWGlEPTB;MUC0Mlk5PiEQvF2=Mkm4V2FPT0WU
NCI-H1770NYXyV2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPNTopHUUN3ME2xNFgvPzh2IN88US=>NHyx[YtUSU6JRWK=
NCI-H82NV[5N3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWi4RZRKUUN3ME2xNVAvQTd4IN88US=>M2P2[3NCVkeHUh?=
NCCITNWXIcYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPNTWM2OD1zMUKuOVI6KM7:TR?=NVTQWZdDW0GQR1XS
KALS-1NHy2UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\NTWM2OD1zMUWuPVQyKM7:TR?=NHrleIdUSU6JRWK=
LB2241-RCCMn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3n5d2lEPTB;MUG2MlY4QSEQvF2=MWnTRW5ITVJ?
HHNYTLOJhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjFTWM2OD1zMUeuN|k2KM7:TR?=MUPTRW5ITVJ?
HD-MY-ZNYrZVI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF25VGdKSzVyPUGxPE41QDhizszNMYfTRW5ITVJ?
EB-3NV\3cZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGKybW1KSzVyPUGyN{4xQTRizszNNHnqTZZUSU6JRWK=
BL-70NHS0WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\rTWM2OD1zMkOuNVI4KM7:TR?=NYD1Xnp5W0GQR1XS
K-562MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfYVW1KUUN3ME2xNlYvOjR3IN88US=>NVezeI1SW0GQR1XS
HT-144MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonTTWM2OD1zM{OuNVY1KM7:TR?=NYfCc3F[W0GQR1XS
PF-382M1TjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HQPGlEPTB;MUO0MlM3OSEQvF2=M2njVHNCVkeHUh?=
RPMI-8226MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYriVlNuUUN3ME2xN|UvODR3IN88US=>NEG0b5lUSU6JRWK=
NCI-H1355M3TOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jnUWlEPTB;MUO1MlU5PyEQvF2=MmjwV2FPT0WU
LXF-289M{X2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2G3bmlEPTB;MUO5Mlc5OSEQvF2=MXvTRW5ITVJ?
NCI-H69MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\xOmlEPTB;MUSyMlk{OiEQvF2=NIXCUHdUSU6JRWK=
SK-MEL-1NHTvW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXoTWM2OD1zNEeuNVMh|ryPMYrTRW5ITVJ?
KARPAS-299MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnwNYd4UUN3ME2xOFkvOTJizszNMWLTRW5ITVJ?
GB-1Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTF2OT6zNlIh|ryPMnu5V2FPT0WU
CMKMlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTlOVRKUUN3ME2xOFkvPTF3IN88US=>M1XEb3NCVkeHUh?=
MPP-89MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHGTWM2OD1zNU[uNFM2KM7:TR?=NX\IbJF1W0GQR1XS
KU812MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mly0TWM2OD1zNkGuPVAzKM7:TR?=MVjTRW5ITVJ?
REHNWjBWVk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHzVHBKSzVyPUG2Nk4yOjVizszNM3H5PXNCVkeHUh?=
NEC8NV25UIJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTF4NT6wNlYh|ryPNV\H[phIW0GQR1XS
KP-N-YSNFK2T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjSWIViUUN3ME2xOlgvOzl3IN88US=>MlLVV2FPT0WU
Ramos-2G6-4C10MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfaS5VKSzVyPUG2PU46OTVizszNMUfTRW5ITVJ?
BeckerNWrae|RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LhOmlEPTB;MUe0MlE5KM7:TR?=NUf6coROW0GQR1XS
LB647-SCLCMn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTF5NT64OFUh|ryPMYHTRW5ITVJ?
LU-139NYrhfZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfve2lKSzVyPUG3PE4xOTlizszNMk\sV2FPT0WU
QIMR-WILMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFG0TmRKSzVyPUG3PU43PDZizszNM{\IbnNCVkeHUh?=
NCI-H1395NHPKeYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTF5OT65PVYh|ryPNEHo[|BUSU6JRWK=
NOMO-1MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3HZZdKSzVyPUG4Nk45PSEQvF2=NHzDVpFUSU6JRWK=
GI-ME-NNUK1VYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTF6Nz65Olkh|ryPMXfTRW5ITVJ?
KMS-12-PENFGwU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF6OT6yO|Mh|ryPNXy2O49iW0GQR1XS
DaudiNHL0bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXviO|E{UUN3ME2xPVEvOTJ6IN88US=>MUjTRW5ITVJ?
LB996-RCCM4HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF7MT62PVkh|ryPNEXUS|ZUSU6JRWK=
NCI-H2107MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTKWXNIUUN3ME2xPVMvPzN7IN88US=>M3:0e3NCVkeHUh?=
SK-PN-DWNGTLTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjobXJKSzVyPUG5OE44OTlizszNNVm3SY8{W0GQR1XS
MC-CARM4KzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfXTWM2OD1{MEKuNlU{KM7:TR?=MUHTRW5ITVJ?
SNB75NXLHU2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJ{MT65OEDPxE1?MWDTRW5ITVJ?
ES4NW\2UHFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLDTWM2OD1{MkOuO|g{KM7:TR?=MXHTRW5ITVJ?
KARPAS-422M4rUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnvelZjUUN3ME2yNlgvOzV{IN88US=>Mnm0V2FPT0WU
NCI-H1648Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\WUFdKSzVyPUKyPU41QDlizszNMXnTRW5ITVJ?
ES6NGrYZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrqSnlKSzVyPUKzPU41OyEQvF2=NUfMN3ZmW0GQR1XS
KNS-81-FDNULQWmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVyw[FhFUUN3ME2yOFEvOTl5IN88US=>MmfYV2FPT0WU
JARNV;qNZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJ3Nj6yNlUh|ryPM1rFV3NCVkeHUh?=
NB1NFjRbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHtell[UUN3ME2yOlAvPTF4IN88US=>NXfM[WNNW0GQR1XS
D-336MGMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7vTWM2OD1{NkCuOlk5KM7:TR?=M2TqfnNCVkeHUh?=
BC-3MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTJ4NT6xO|gh|ryPMnLtV2FPT0WU
HCC2218Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjHRWZVUUN3ME2yOlYvPDF3IN88US=>MkfYV2FPT0WU
TE-9MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLxdlhKSzVyPUK2Ok43OjdizszNMVzTRW5ITVJ?
LB1047-RCCM1rUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJ4Nj63OVMh|ryPMoDCV2FPT0WU
CTB-1NGPPfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnVeFdKSzVyPUK2PU46PzNizszNM{LOZnNCVkeHUh?=
NB7Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYq3RYdpUUN3ME2yO|Eh|ryPNWHrUodIW0GQR1XS
ST486NFiyW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjBbllKSzVyPUK3O{41OTJizszNMVHTRW5ITVJ?
HCC1187M3\yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXIcldKSzVyPUK4Nk45OTFizszNMWPTRW5ITVJ?
NCI-SNU-16NX3qOYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLIWmszUUN3ME2yPFQvOjR6IN88US=>MmHLV2FPT0WU
COR-L279NYjQ[2ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUH2NGkzUUN3ME2yPVEvPTh2IN88US=>NEHBPHVUSU6JRWK=
ES8NGjVO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnDZ2hKSzVyPUK5OE4yQDJizszNMlKyV2FPT0WU
U-698-MMorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;qWGRwUUN3ME2yPVgvOjR|IN88US=>NWPtdohDW0GQR1XS
HELMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nTXGlEPTB;M{C5MlE1QSEQvF2=Mn\lV2FPT0WU
KINGS-1MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWG2SZR1UUN3ME2zNVAvPjd2IN88US=>NFLHS5BUSU6JRWK=
KY821NWnaVVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv2TWM2OD1|M{[uOVk2KM7:TR?=NWGxbYpkW0GQR1XS
MZ1-PCNH7iTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmP6TWM2OD1|NEWuOlE5KM7:TR?=MVzTRW5ITVJ?
LS-411NMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPDTWM2OD1|NUSuOlYh|ryPNGTBeIhUSU6JRWK=
SIG-M5MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXyxXZY6UUN3ME2zOVkvPzh{IN88US=>MY\TRW5ITVJ?
HTNH;LWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTN4Nz63NVEh|ryPMYrTRW5ITVJ?
HC-1M1PQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XwOGlEPTB;M{[3Mlc5PyEQvF2=NWTHelEyW0GQR1XS
NCI-H1694NX3Sbld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTN5Mj65N|Qh|ryPNHvNPZJUSU6JRWK=
BB65-RCCNGLTT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTncoNwUUN3ME2zO|YvOjR3IN88US=>MoTTV2FPT0WU
HAL-01NWTJNW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUSxWoM5UUN3ME2zO|kvQDN6IN88US=>NUf6cpU3W0GQR1XS
ARH-77NFjYNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTN7ND6wNFgh|ryPMmr6V2FPT0WU
MZ7-melM1fQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTN7Nz6yN|Mh|ryPMojEV2FPT0WU
SIMANHztcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXifGlKSzVyPUSwN{46OzNizszNM3LWdnNCVkeHUh?=
DG-75MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlSwTWM2OD12MUWuOlk5KM7:TR?=Mlm3V2FPT0WU
HUTU-80MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\kTWM2OD12MUmuNVg2KM7:TR?=M4DOcXNCVkeHUh?=
KNS-42MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzyTWM2OD12MkWuPFE2KM7:TR?=NXXlNZY6W0GQR1XS
SH-4NFvWZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTR{Nz61OlUh|ryPNVP0XYFTW0GQR1XS
L-540MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTR|MT6wN|Eh|ryPMXLTRW5ITVJ?
NB10M4nt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;xemlEPTB;NESxMlI{PCEQvF2=MmDZV2FPT0WU
ES1NYC2[Y95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1S2SWlEPTB;NEWyMlc2OyEQvF2=NHHhOZZUSU6JRWK=
KMOE-2NFu2SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfmbXdKSzVyPUS1Ok44OTFizszNM2fZTHNCVkeHUh?=
MC116M3TaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C0bmlEPTB;NEW4MlEyPiEQvF2=M4TYSHNCVkeHUh?=
RCC10RGBMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEO4UXhKSzVyPUS2NE4xODVizszNMWfTRW5ITVJ?
RL95-2NUns[lBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTqdZhuUUN3ME20OlAvOjN5IN88US=>MlvOV2FPT0WU
RajiMkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmP2TWM2OD12NkiuNVQ{KM7:TR?=M1z3[3NCVkeHUh?=
CAS-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR5Mj6wO|Mh|ryPNHTmTmdUSU6JRWK=
Calu-6NGPYNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLWTWM2OD12N{WuNlY2KM7:TR?=M3P3XXNCVkeHUh?=
KG-1NXHic5B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nsRWlEPTB;NEe4MlQ1KM7:TR?=MlfQV2FPT0WU
LB771-HNCM4HIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDvTGoxUUN3ME20PFIvOjN{IN88US=>MX\TRW5ITVJ?
ACNMl7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W2[GlEPTB;NEmzMlU6QSEQvF2=NHTONWhUSU6JRWK=
KM12M1ixcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTR7Nj61PFkh|ryPNHLMOm5USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Hedgehog cell assay This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack

Cell Assay: [2]

Cell lines SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
Concentrations Dissolved in DMSO, final concentration 3 μM
Incubation Time 4 days
Method Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).

Animal Study: [2]

Animal Models Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
Formulation Dissolved in DMSO, and diluted in saline
Dosages 50 mg/kg/day
Administration Subcutaneous injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Peukert S, et al. Bioorg Med Chem Lett, 2009, 19(2), 328-331.

[2] Berman DM, et al. Nature, 2003, 425(6960), 846-851.

view more

Chemical Information

Download Cyclopamine SDF
Molecular Weight (MW) 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms 11-deoxojervine
Solubility (25°C) * In vitro DMF 10 mg/mL warming (24.29 mM)
Ethanol 2 mg/mL warming (4.85 mM)
Water <1 mg/mL (<1 mM)
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Hedgehog/Smoothened Products

  • Smoothened Agonist (SAG) HCl

    Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

  • SB225002

    SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

  • SB-334867

    SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

  • GANT61

    GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Purmorphamine

    Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.

  • LDE225 (NVP-LDE225,Erismodegib)

    LDE225 (NVP-LDE225,Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

  • Taladegib (LY2940680)

    Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.

  • Glasdegib (PF-04449913)

    Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.

  • SANT-1

    SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.

    Features:Attenuates SAG stimulation of Shh-LIGHT2 cells to a greater extent relative to other antagonists.

Recently Viewed Items

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us